CLSD
Clearside Biomedical Inc

5,188
Loading...
Loading...
News
all
press releases
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of +50.00% and +87.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of -14.29% and -76.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Zacks·4mo ago
News Placeholder
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
Zacks·4mo ago
News Placeholder
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks·4mo ago
News Placeholder
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
chainwire·4mo ago
News Placeholder
Clearside Biomedical's CLS-AX Shows Promise in Phase 2b Trials, Yi Chen Maintains Buy Rating with $5 Price Target
Clearside Biomedical (CLSD Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H...
TipRanks Financial Blog·1y ago
News Placeholder
Buy Rating Affirmed for Clearside Biomedical on Promising Phase 3 Results and Innovative Drug Delivery System
H.C. Wainwright analyst Yi Chen has reiterated their bullish stance on CLSD stock, giving a Buy rating today. Yi Chen has given his Buy rating due...
TipRanks Financial Blog·1y ago
News Placeholder
Oppenheimer Sticks to Its Buy Rating for Clearside Biomedical (CLSD)
In a report released today, Andreas Argyrides from Oppenheimer maintained a Buy rating on Clearside Biomedical (CLSD Research Report), with a pri...
TipRanks Financial Blog·1y ago
News Placeholder
Buy Rating Affirmed: Clearside Biomedical's Innovative Drug Delivery and Promising Clinical Trials
Serge Belanger, an analyst from Needham, maintained the Buy rating on Clearside Biomedical (CLSD Research Report). The associated price target re...
TipRanks Financial Blog·1y ago

Latest CLSD News

View

Advertisement. Remove ads.

Advertisement. Remove ads.